1 / 48

BME 301

BME 301. Lecture Fifteen. Review of Lecture 14. Cervical cancer 2 nd Leading cause of cancer death in women in world Caused by infection with HPV Precancer cancer sequence Precancer is very common Screening & Detection Pap smear; colposcopy + biopsy

herman
Download Presentation

BME 301

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. BME 301 Lecture Fifteen

  2. Review of Lecture 14 • Cervical cancer • 2nd Leading cause of cancer death in women in world • Caused by infection with HPV • Precancercancer sequence • Precancer is very common • Screening & Detection • Pap smear; colposcopy + biopsy • Reduces incidence and mortality of cervical cancer • Insufficient resources to screen in developing countries • New technologies • Automated reading of Pap smears  reduce FN rate • HPV testing • Optical technologies

  3. Ovarian Cancer Early Detection

  4. Female Reproductive System 1 uterine fundus 6 endocervix 11 ovary 2 cavity of the uterus 7 ectocervix 12 uterine tube 3 endometrium 8 lateral fornix 13 fimbriae of uterine tube 4 myometrium 9 vagina 5 uterine isthmus 10 ovarian ligament

  5. Ovarian Cancer: 2004 • United States • 25,580 new cases in US • 4% of all cancers in women • 16,090 deaths in US • Worldwide • 190,000 new cases in world • 114,000 deaths worldwide • Highest rates in Scandinavia, Eastern Europe, USA, and Canada

  6. Ovarian Cancer: World

  7. Ovarian Cancer • Screening: • No adequate screening tests available • Treatment: • Surgery, radiation therapy, chemotherapy • 5 year survival • All stages: 53% • Localized disease (Stage I): 90% • Metastatic (Stage III-IV): 15-20% • 70% of women diagnosed at these stages

  8. Ovarian Cancer “Whispers” • Symptoms: • Unexplained change in bowel and/or bladder habits such as constipation urinary frequency, incontinence • Gastrointestinal upset: gas, indigestion, nausea • Unexplained weight loss or weight gain • Pelvic and/or abdominal pain or discomfort • Pelvic and/or abdominal bloating or swelling • A constant feeling of fullness • Fatigue • Abnormal or postmenopausal bleeding • Pain during intercourse

  9. Risk Factors for Ovarian Cancer • Personal or family history of breast, ovarian, endometrial, prostate or colon cancer • One or more first-degree relatives (mother, sister, daughter) who have ovarian cancer • Carrying a BRCA1 or BRCA2 gene mutation • Hormonal treatment for infertility • Uninterrupted ovulation • Infertility • never used birth control pills • never pregnant • Increasing age • Use of high dose estrogen for long periods without progesterone may be a risk factor

  10. My Mother-In-Law

  11. Dr. Molly Brewer

  12. In The News • http://msnbc.msn.com/id/3933580/

  13. Your CONFIDENTIAL Test Results • Possible Results: • Automatic 100% on Exam 2 • Lose 10 points on Exam 2 • Lose 1 point on Exam 2 • No effect on Exam 2 score

  14. Ovary http://www.deltagen.com/target/histologyatlas/atlas_files/female_rep/ovary_10x.jpg

  15. Ovary http://www.vacadsci.org/jsr/ovary.jpg

  16. Early Detection of Ovarian Cancer • Pelvic and rectal examination: • Feel uterus and ovaries to find abnormality in shape or size • Unlikely to detect early stage ovarian cancer • CA-125: • 80% of women with advanced ovarian cancer have elevated CA125 • Used to monitor ovarian cancer after diagnosis is surgically confirmed - sensitive indicator of persistent or recurrent disease • Very unreliable for detecting early cancer • Very unreliable for detecting cancer in pre-menopausal women • Elevated by conditions such as pregnancy, endometriosis, uterine fibroids, liver disease, and benign ovarian cysts • Transvaginal Ultrasound: • Use high-frequency sound waves to create pictures of ovaries • Can detect ovarian malignancies in asymptomatic women • Poor accuracy in detecting early stage disease

  17. Performance of CA125 • Overall performance in Norwegian study: • Sensitivity of 30-35% • Specificity was 95.4% • Performance by stage: • Sensitivity for Stage I cancers: 29 - 75% • Sensitivity for Stage II cancers: 67 - 100%

  18. Transvaginal Sonography • Sensitivity = 100% • Specificity = 96% http://www.infertilitytutorials.com/images/transvaginal_ultrasound.jpg http://www.ivf-infertility.com/images/polycystic_ovary.jpg

  19. Diagnostic Laparoscopy Complication Rate = 0.5 – 1% http://www.aiof.com/html/images/lapro.jpg

  20. Screening Scenarios • Scenario #1: • Screen 1,000,000 women with CA125 • p = .0001 (100 cancers) • Se=35%, Sp=98.5% • Cost = $30 • Follow with laparoscopy • Complication rate = 1% • Cost=$2,000 • TP=35 FP=14,999 Complications=150 • PPV =0.23% NPV =99.99% • Cost per cancer found = $1,716,200

  21. Screening Scenarios • Scenario #2: • Screen 1,000,000 women with transvaginal US • P = .0001 (100 cancers) • Se=100%, Sp=96% • Cost = $150 • Follow with laparoscopy • Complication rate = 1% • Cost=$2,000 • TP=100 FP=39,996 Complications=401 • PPV =0.25% NPV =100% • Cost per cancer found = $300,672

  22. Screening Scenarios • Scenario #3: • Screen 1,000,000 women >age 50 with TVUS • P = .0005 (500 cancers) • Se=100%, Sp=96% • Cost = $150 • Follow with laparoscopy • Complication rate = 1% • Cost=$2,000 • TP=500 FP=39,980 Complications=405 • PPV =1.24% NPV =100% • Cost per cancer found = $60,670

  23. Screening Scenarios • Scenario #3 cont.: • Screen 1,000,000 women > age 50 with TVUS • P = .0005 (500 cancers) • Se=100%, Sp=??% • Cost = $150 • How high does Sp need to be for PPV to reach 25%? • Sp = 99.985%

  24. Does Ultrasound Screening Work? • Two studies of over 10,000 low-risk women: • The positive predictive value was only 2.6% • Ultrasound screening of 100,000 women over age 45 would: • Detect 40 cases of ovarian cancer, • Result in 5,398 false positives • Result in over 160 complications from diagnostic laparoscopy • Jacobs I. Screening for early ovarian cancer. Lancet; 2:171-172, 1988.

  25. Does CA125/US Screening Reduce Mortality? • Decision Analysis: • Ovarian cancer screening with CA 125 levels and/or transvaginal sonography in a cohort of 40-year-old women • Screening increased the average life expectancy in this population by less than one day per woman screened • Skates SJ, Singer DE. Quantifying the potential benefit of CA125 screening for ovarian cancer. J Clin Epidemiol 1991;44:365-380. • Schapira MM, Matchar DB, Young MJ. The effectiveness of ovarian cancer screening: a decision-analysis model. Ann Intern Med 1993;118:838-843

  26. Methodology Overview Cost-Effectiveness Analysis

  27. Ongoing Trials • United Kingdom • 200,000 postmenopausal women • CA 125 level plus transvaginal ultrasound examination • Transvaginal ultrasound alone • No screening • United States: • 37,000 women (aged 55–74) • Annual CA 125 level and transvaginal ultrasound examination • No screening • Europe: • 120,000 postmenopausal women • No screening, • Transvaginal ultrasound at intervals of 18 months • Transvaginal ultrasound at intervals of 3 years http://www.mja.com.au/public/issues/178_12_160603/and10666_fm.pdf

  28. Your CONFIDENTIAL Test Results • Possible Results: • Automatic 100% on Exam 2 • Lose 10 points on Exam 2 • Lose 1 point on Exam 2 • No effect on Exam 2 score

  29. New Screening Tool • Current screening tests look for 1 protein: • CA125 • PSA • Many serum proteins • Can complex fingerprint predictive of cancer can be identified? • PROTEOMICS: • Don’t try to understand disease mechanisms • Use proteomics to analyze patterns made by all proteins in the blood, without even knowing what they are

  30. How do we measure serum proteins? • Mass Spectrometry: • Serum proteins are vaporized, given an electric charge and propelled down a tube • How fast they make the trip depends on their mass • Produces graph that shows distribution of masses in the sample • Use computer program to analyze patterns and distinguish blood from patients with cancer and from those without

  31. Typical Data mass/charge 15,200 values of intensity vs. mass/charge

  32. Technology Overview Mass Spectrometry

  33. Magnetic field chamber Sample goes here Mass Spectrometer

  34. What is Mass Spectrometry? • Chemically pure sample: • Bombard with electron beam of sufficient energy to fragment molecule • Positively charged fragments produced are accelerated in vacuum through magnetic field and sorted on basis of mass-to-charge ratio • Most ions produced carry unit positive charge, • Value m/charge is equivalent to molecular weight of fragment • Analyze by re-assembling fragments, working backwards to generate original molecule http://chipo.chem.uic.edu/web1/ocol/spec/MS.htm

  35. Sample Data

  36. How do we apply to serum proteins? • Mixture of proteins • Bombard with electron beam • Break into charged fragments, normally +1, • Tiny fragments are then run through thin wires and sprayed out of a nozzle through a magnetic field in a vacuum • The way in which they react inside this magnetic field is highly predictable depending on mass to charge ratio

  37. New Screening Tool: WA7 • Blood test to detect ovarian cancer • Examined thousands of proteins • Found a few that appear to be hallmarks of ovarian cancer • Se = 50/50 = 100% • Sp = 63/66 = 95% • PPV = 94% • "The most important next goal is validating the promise of these results in large, multi-institutional trials." • Lance Liotta, M.D., Ph.D.

  38. Data Analysis Training Validation

  39. Useful M/Z: 534 989 2111 2251 2465

  40. Comparative Analysis Useful M/Z: 534 989 2111 2251 2465

  41. OvaCheck • Quest Diagnostics and LabCorp: • Will analyze blood samples sent by doctors, rather than sell test kits to doctors and hospitals • Tests performed at a central location do not require F.D.A. approval • Will be available in a few months • Cost: $100-$200

  42. Response • http://msnbc.msn.com/id/3933580/

  43. Response • Dr. Eleftherios P. Diamandis, head of clinical biochem at Mount Sinai Hospital in Toronto. • "If you don't know what you're measuring, it's a dangerous black-box technology… They are rushing into something and it could be a disaster.“ • Dr. Nicole Urban, head of gynecologic cancer research at the Fred Hutchinson Cancer Research Center in Seattle. • "Certainly there's no published work that would make me tell a woman she should get this test.“ • Dr. Beth Karlan, director of gynecologic oncology at Cedars-Sinai Medical Center • "Before you mass-market to the uninformed, fearful population, it should be peer-reviewed," • When asked whether she would recommend her patients not get tested, she said: "It doesn't matter what I recommend. They are going to do it anyway." http://www.ovarian.org/press.asp?releaseID=263

  44. Your CONFIDENTIAL Test Results • Possible Results: • Automatic 100% on Exam 2 • Lose 10 points on Exam 2 • Lose 1 point on Exam 2 • No effect on Exam 2 score

  45. Assignments Due Next Time • WA9 • Presentations: • April 8th • E-mail from Mark Carlson with details • Exam Two: • April 13th • Will cover Vaccines – Cancer Detection

  46. Analytical Methods for Technology Assessment Scott B. Cantor, Ph.D. The University of Texas M. D. Anderson Cancer Center Department of Biostatistics Section of Health Services Research

  47. Acknowledgments • Society for Medical Decision Making and SMDM Education Committee • Basic Diagnostic Test Evaluation Short Course • Michael J. Barry, MD, General Medicine Division, Massachusetts General Hospital, Boston, MA • Robert M. Centor, MD, Division of General Internal Medicine, University of Alabama at Birmingham, Birmingham, AL • John R. Clarke, MD, Department of Surgery, Medical College of Pennsylvania, Philadelphia, PA • Albert G. Mulley, Jr., MD, MPP, General Medicine Division, Massachusetts General Hospital, Boston, MA

More Related